dc.contributor.author |
Khairullin I. |
|
dc.contributor.author |
Esin R. |
|
dc.contributor.author |
Esin O. |
|
dc.date.accessioned |
2018-09-19T22:41:51Z |
|
dc.date.available |
2018-09-19T22:41:51Z |
|
dc.date.issued |
2016 |
|
dc.identifier.issn |
2074-2711 |
|
dc.identifier.uri |
https://dspace.kpfu.ru/xmlui/handle/net/145371 |
|
dc.description.abstract |
Objective: to evaluate cognitive functions in patients with type 2 diabetes mellitus (DM2) and hypertension and the efficacy of Ginkgo biloba extract Egb 761®. Patients and methods: 120 patients with DM2 and 50 hypertensive patients with no complications or a history of stroke and/or myocardial infarction, without active complaints of hypomnesia and other cognitive functions were examined. The exclusion criteria were prior stroke and/or myocardial infarction; clinically significant diseases of the peripheral arteries and major arteries of the head; DM2 decompensation; glomerular filtration rate <60 ml/min; proliferative retinopathy; and other endocrine diseases. The investigators used the following methods for the evaluation of cognitive functions: the Mini-Mental State Examination, the Montreal Cognitive Assessment, and the hand-eye coordination test (Parts A and B). Results and discussion: 85% of the patients with DM2 were found to have cognitive impairments (CI): disorders of attention, short-term memory, and thinking speed. Out of them, 82.5% had moderate CI and 2.5% had dementia. 30% of the hypertensive patients were diagnosed as having moderate CIs and 10% had dementia. At the same time, the degree of CI was higher in the patients with MD2 than in those with hypertension. The use of Egb 761® 240 mg/day for 3 months had a statistically significant positive impact on cognitive functions (improvements in short-term memory, concentration, and thinking speed) and everyday activity. Conclusion: The authors consider that CIs are the first sign of encephalopathy in DM2. It is also noted that DM2 has a more pronounced impact on cognitive functions than hypertension. Egb 761® can be used as an effective drug to treat CI in these diseases. |
|
dc.relation.ispartofseries |
Nevrologiya, Neiropsikhiatriya, Psikhosomatika |
|
dc.subject |
Cognitive functions |
|
dc.subject |
Cognitive impairment |
|
dc.subject |
Diabetes mellitus type 2 |
|
dc.subject |
Diabetic encephalopathy |
|
dc.subject |
Egb 761 ® |
|
dc.subject |
Hypertension |
|
dc.title |
Cognitive impairment in diabetes mellitus and hypertension, a possibility of correction |
|
dc.type |
Article |
|
dc.relation.ispartofseries-issue |
3 |
|
dc.relation.ispartofseries-volume |
8 |
|
dc.collection |
Публикации сотрудников КФУ |
|
dc.relation.startpage |
48 |
|
dc.source.id |
SCOPUS20742711-2016-8-3-SID85017093375 |
|